Clinical characteristics and long-term outcome of patients with POEMS syndrome in China

Ann Hematol. 2011 Jul;90(7):819-26. doi: 10.1007/s00277-010-1149-0. Epub 2011 Jan 8.

Abstract

POEMS syndrome is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. This study reviewed the clinical characteristics and long-term outcome of 99 consecutive Chinese patients with newly diagnosed POEMS syndrome in a single institute. The median age of 99 patients was 45 years, and the ratio of men/women was 1.4. The median time from onset of symptoms to diagnosis was 18 months. The typical five features of peripheral neuropathy, organomegaly, endocrinopathy, M protein, and skin change remained to be essential for patients with POEMS syndrome in China. The unusual features like pulmonary hypertension (36%) and renal impairment (37%) were not uncommon in China. Eighty-three percent patients were alive after follow-up time of 25 months, and 10% patients had survived more than 60 months. Melphalan-based therapy (OR, 0.076; 95% CI, 0.02-0.285) and normal renal function (OR, 0.246; 95% CI, 0.076-0.802) were independent prognostic factors for the survival of patients with POEMS syndrome. In conclusion, POEMS syndrome in Chinese patients was a multi-systemic disease with clinical features similar to non-Chinese ones. Active therapy can effectively improve the prognosis of patients with POEMS syndrome.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Castleman Disease / pathology
  • Castleman Disease / physiopathology
  • China
  • Female
  • Humans
  • Kidney / metabolism
  • Male
  • Melphalan / therapeutic use
  • Middle Aged
  • POEMS Syndrome / diagnosis*
  • POEMS Syndrome / drug therapy
  • POEMS Syndrome / pathology*
  • POEMS Syndrome / physiopathology
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Melphalan